Program Description & Educational Objectives

In this activity, experts in the management of chronic myeloid leukemia (CML) discuss the recently changed therapeutic landscape for the management of newly diagnosed patients who present with chronic-phase disease. The experts will discuss how different attempts at tyrosine kinase inhibitor intensification in this setting—from the use of second-generation agents to higher doses of first-generation TKIs—have been explored in clinical trials, and review which strategies have been validated for use in newly diagnosed patients. The faculty will also address clinical decision-making in the first-line setting through a series of case vignettes that will cover therapy selection and management of treatment-related adverse events for patients with CML.

Upon completion of this activity, participants will be able to:

• Cite and interpret new safety and efficacy data on the use of second-generation tyrosine kinase inhibitors in newly diagnosed patients with chronic-phase CML
• Summarize current data on TKI intensification with first-generation agents in the setting of chronic-phase CML
• Select and appropriately administer TKI therapy in patients with newly diagnosed CML based on patient characteristics, potential for robust response, and other relevant criteria
• Appropriately manage treatment-related complications in patients with chronic-phase CML receiving TKI therapy

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice oncology nurses, pharmacists, and other clinicians involved in the management of patients with CML.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: August 22, 2011 - August 21, 2012
Time to Complete: 30 minutes

Faculty & Disclosure / Conflict of Interest Policy

All faculty AND staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

Course Director and Moderator

Michael W. N. Deininger, MD, PhD
Chief, Division of Hematology and Hematologic Malignancies
M. M. Wintrobe Professor of Medicine
University of Utah
Huntsman Cancer Institute
Salt Lake City, Utah

Michael W. N. Deininger, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for ARIAD Pharmaceuticals, Inc.; Bristol-Myers Squibb; and Novartis Pharmaceuticals Corporation.
Grant/Research Support from Bristol-Myers Squibb; Genzyme Corporation; the National Institutes of Health (NIH); Novartis Pharmaceuticals Corporation; and The Leukemia & Lymphoma Society (LLS).
Honoraria from ARIAD Pharmaceuticals, Inc.; Bristol-Myers Squibb; and Novartis Pharmaceuticals Corporation.
Advisory Board for ARIAD Pharmaceuticals, Inc.; Bristol-Myers Squibb; and Novartis Pharmaceuticals Corporation.
Other Financial or Material Support from Blood in the form of editorial involvement.

Interviewee

Neil P. Shah, MD, PhD
Associate Professor
Division of Hematology/Oncology
Co-Leader, Hematopoietic Malignancies Program
Helen Diller Family Comprehensive Cancer Center
Edward A. Ageno Distinguished Professor
University of California, San Francisco
San Francisco, California

Neil P. Shah, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bristol-Myers Squibb.

Content Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca currently has no financial interests/relationships or affiliations in relation to this activity.

All additional planning committee members, PVI, PeerView Institute for Medical Education, Inc. staff, and Purdue University College of Pharmacy staff have no relationships to disclose.

Sponsorship, Credit & Support

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

The Purdue University College of Pharmacy designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Purdue University Continuing Nursing Education, West Lafayette, IN (ISNA No. CNEP 11-03, Exp. 06/1/2014) is an approved provider of continuing nursing education by the Indiana State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

This activity has been approved for 0.5 contact hour(s).

Note: Not all state nursing boards will accept programs less than 1.0 hour in length for credit. Please click here to find out the status of your state.

Pharmacists

Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-11-117-H04-P, 0.5 contact hours (0.05 CEUs).
Release Date: August 22, 2011 Expiration Date: August 21, 2012

This CME/CNE/CPE activity is jointly sponsored by Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.